Home|Journals|Articles by Year|Audio Abstracts

Original Article

IJMDC. 2023; 7(3): 418-424

Contemporary aminophylline use for status asthmaticus in pediatric ICUs: a questionnaire-based study

Ahmed Abdullah Alsaqer, Munirah Abdulrahman Alrobian, Abdulaziz Alolayan, Ali Alqahtani, Hend Bafagih, Abdullah Qasem.


Background: Status asthmaticus is severe acute exacerbation asthma that results in respiratory failure due to the failure of conventional treatment. Aminophylline is one of the methylxanthines used to manage status asthmaticus in the pediatric intensive care unit (PICU). However, aminophylline’s role in managing severe asthma among children is still controversial, and PICUs still use it. There is no data on using aminophylline in Saudi Arabia. This study aimed at assessing the use and causes of using aminophylline in the PICU and the perception of pediatricians on using aminophylline in the PICU.
Methods: A cross-sectional study was conducted on pediatric physicians working in PICUs employing pre-validated questionnaire. The Statistical Package for the Social Sciences program was used to analyze the retrieved data.
Results: One hundred seventy-one pediatricians participated in the study; 85.4% reported IV aminophylline for acute asthma exacerbation, and 69% reported using it if the patient did not improve on other medications. About 68.4% and 83% considered IV aminophylline an effective and safe option, respectively. The side effects of IV aminophylline reported were arrhythmia at 75.3% and gastrointestinal tract side effects at 15.1%.
Conclusion: Aminophylline was found highly used in PICUs in Saudi Arabia; this can be attributed to the perception of pediatricians, as it is a safe and effective treatment option.

Key words: Aminophylline, causes, usage, status asthmaticus, pediatrics, PICU.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.